-
Published on Aug 11, 2016
Life science group ValiRx Plc (LON:VAL) has got the green light to start trials of a flagship lung cancer drug.
ValiRx has received approval from authorities in the former Soviet republic of Georgia to begin dosing patients in a phase II clinical trial of VAL401.
ValiRx has received approval from authorities in the former Soviet republic of Georgia to begin dosing patients in a phase II clinical trial of VAL401.
The news means ValiRx's joint venture ValiSeek to start identifying and recruiting people for screening.
ValiSeek's chief executive Suzanne Dilly said: "It is very satisfying to have received confirmation from the regulatory experts that the trial has been correctly constructed and that the process of selecting patients for dosing can begin.
"After several years of preparation and pre-clinical testing, it is exciting to know we can expect results to start arriving in the coming months."
http://www.4-traders.com/VALIRX-PLC-22619385/
No comments:
Post a Comment